↑ 疾患リストへ ← 戻る

 161. 家族性良性慢性天疱瘡 [臨床試験数:4,薬物数:7(DrugBank:1),標的遺伝子数:1,標的パスウェイ数:1] 

Searched query = "Familial benign chronic pemphigus", "Benign familial pemphigus", "Hailey-Hailey disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000373-80-FR24/05/201823 July 2018A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey DiseaseA Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hailey-Hailey Disease - DERM-101Darier’s Disease or Hailey-Hailey Disease
MedDRA version: 20.0 Level: LLT Classification code 10011860 Term: Darier's disease System Organ Class: 100000004850
MedDRA version: 20.1 Level: LLT Classification code 10019029 Term: Hailey-Hailey disease System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Product Name: LX3305 250 mg capsule
Product Code: LX3305
Pharmaceutical Form: Capsule
INN or Proposed INN: None
CAS Number: 1078151-47-9
Current Sponsor code: LX3305 Dihydrate
Other descriptive name: (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 250-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Dermecular Therapeutics, Inc.AuthorisedFemale: yes
Male: yes
40Phase 1;Phase 2France
2NCT02782702September 201510 December 2018Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey DarierHailey-Hailey Disease;Darier DiseaseDrug: Botulism Toxin TreatmentUniversity Hospital, ToulouseNot recruiting18 YearsN/AAll30Phase 1
3EUCTR2013-004562-33-IT17/12/201319 February 2018PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTSPHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTSSYMPTOMATIC HHD PATIENTS
MedDRA version: 16.1 Level: LLT Classification code 10019029 Term: Hailey-Hailey disease System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: SCENESSE
Product Name: SCENESSE
Pharmaceutical Form: Implant
ISTITUTI FISIOTERAPICI OSPITALIERIAuthorisedFemale: yes
Male: yes
10Phase 2Italy
4JPRN-UMIN0000101912013/04/012 April 2019The examination of the clinical response of celecoxib in Darier's disease and Hailey-Hailey diseaseDrier's disease Hailey-Hailey diseasecelecoxibJuntendo university gradurate school of medicineNot Recruiting20years-oldNot applicableMale and Female10Not selectedJapan